Department of Urinary Surgery, MeiZhou People's Hospital, Meizhou Affiliated Hospital of Sun Yat-sen University, Huangtang Road, Meijiang District, Meizhou, Guangdong Province, 514031, People's Republic of China.
J Cancer Res Clin Oncol. 2012 Jan;138(1):11-22. doi: 10.1007/s00432-011-1067-0. Epub 2011 Sep 24.
To explore the expression of receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB1) and their role in clear cell renal cell carcinoma (CCRCC) development and progression.
Expression of RAGE and HMGB1 was examined in RCC using tissue microarrays. In vitro, quiescent or RAGE-reduced RCC cells were subjected to treatment with HMGB1 and harvested for detecting ERK1/2 phosphorylation via Western blot. Further cell proliferation, migration and invasion were evaluated by Ki-67 immunostaining, wound healing and matrigel invasion assay, respectively.
①Elevated co-expression of RAGE and HMGB1 in CCRCC was correlated positively with patients' clinical parameters including tumor size, nuclear Fuhrman grade and clinical stage. ②HMGB1 incubation induced ERK1/2 activation in a time- and dose-dependent manner, which could be completely blocked by U0126 (MEK1/2 inhibitor) and partially reversed by RAGE knockdown. ③RAGE knockdown partially reversed the promoted effect of cell proliferation, migration and invasion induced by HMGB1.
HMGB1 promotes the development and progression of CCRCC via ERK1/2 activation, which is partially mediated by RAGE.
探讨晚期糖基化终产物受体(RAGE)和高迁移率族蛋白 B1(HMGB1)的表达及其在透明细胞肾细胞癌(CCRCC)发生发展中的作用。
使用组织微阵列检测 RCC 中 RAGE 和 HMGB1 的表达。在体外,使静止或 RAGE 减少的 RCC 细胞接受 HMGB1 处理,并通过 Western blot 检测 ERK1/2 磷酸化。进一步通过 Ki-67 免疫染色、划痕愈合和基质胶侵袭测定分别评估细胞增殖、迁移和侵袭。
①CCRCC 中 RAGE 和 HMGB1 的高共表达与患者的临床参数(包括肿瘤大小、核 Fuhrman 分级和临床分期)呈正相关。②HMGB1 孵育以时间和剂量依赖的方式诱导 ERK1/2 激活,该激活可被 U0126(MEK1/2 抑制剂)完全阻断,并可部分被 RAGE 敲低逆转。③RAGE 敲低部分逆转了 HMGB1 诱导的细胞增殖、迁移和侵袭的促进作用。
HMGB1 通过 ERK1/2 激活促进 CCRCC 的发生发展,其部分由 RAGE 介导。